CA Patent

CA3303671A1 — Treating spondyloarthritic and psoriatic conditions with upadacitinib

Assigned to AbbVie Inc · Expires 2026-03-31 · 0y expired

What this patent protects

Provided is the JAKI inhibitor upadacitinib free base or a pharmaceutically acceptable salt thereof for use in methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (Ps…

USPTO Abstract

Provided is the JAKI inhibitor upadacitinib free base or a pharmaceutically acceptable salt thereof for use in methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO). In various aspects, upadacitinib free base or a pharmaceutically acceptable salt thereof is for use in methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO).

Drugs covered by this patent

Patent Metadata

Patent number
CA3303671A1
Jurisdiction
CA
Classification
—
Expires
2026-03-31
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.